由于制造问题,林业发展局停止了Johnson & Johnson肺癌药物Rybrevant的新版本。 FDA halts new version of Johnson & Johnson's lung cancer drug Rybrevant due to manufacturing issues.

美国食品和药物管理局已向约翰逊公司发出完整的回复信, 要求其使用皮下注射的肺癌药物Rybrevant, 由于在制造设施检查期间发现的问题. The FDA has issued a complete response letter to Johnson & Johnson for a subcutaneous version of their lung cancer drug Rybrevant, due to issues found during a manufacturing facility inspection. 这一决定不影响Rybrevant目前的IV配方或其有效性和安全性。 This decision does not affect Rybrevant's current IV formulation or its efficacy and safety. Johnson & Johnson正与林业发展局合作解决这些问题,并希望很快向患者提供新版本。 Johnson & Johnson is working with the FDA to address the issues and hopes to bring the new version to patients soon.